MDMichael David

Michael David

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael David has a total of 163 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Piperacillin/Tazobactam Solution Concentration on the Infusion Rate of Portable Elastomeric Pumps (‘EMPs’) in (HITH): A Retrospective Review of Administered and Residual Volumes

    by Toni Docherty, Jenny Schneider, Joyce Cooper, Mark Robertson, Eloise Warren, Catherine Palmqvist, Jessica Pearce, Marte Viljoen, Michael David

    Importance: Piperacillin/tazobactam solutions are frequently administered as 24-hour continuous intravenous infusions to patients in Hospital in the Home (HITH) programs and the accuracy of administration from elastomeric pumps (‘EMPs’) is important. Objective: This study aimed to review the effect of piperacillin/tazobactam solution concentration on the rate of infusion from ‘EMPs’ to patients in the clinical HITH setting, by reviewing the volumes of residual and administered solution. Design: This retrospective audit was conducted from 6/11/2021 to 14/6/2023 and the following information was collected for patients treated with piperacillin/tazobactam EMPs: patient details, treatment indication, EMP solution concentration, time of EMP attachment/detachment, volume of antibiotic solution remaining (if any), EMP type/brand, central line type, and central line issues (if any). Setting: This study was conducted in the Central Coast Health District (CCLHD) HITH in New South Wales, Australia. Participants: Patients treated with 24-hour continuous intravenous infusions of piperacillin/tazobactam via EMPs on the CCLHD HITH service. Results: For all EMPs over all times, a median residual volume of 30mL (IQR: 0-50mL) was recorded (n=2152). Piperacillin/tazobactam 75mg/mL (18g/240mL) EMPs had a median residual volume of 50mL (IQR 20-70mL) when removed at ‘all times’ (n=170) and ‘=24 hours’ (n=184). Residual volumes >15% occurred 48% of the time when removed ‘=24 hours’ (n=325). Piperacillin/tazobactam 75mg/mL (18g/240mL) EMPs were significantly less likely to be removed (at ≥24 hours) with ≤15% residual volume compared to the piperacillin/tazobactam 37.5mg/mL (9g/240mL; p<0.001) or 56.25mg/mL (13.5g/240mL; p=0.008) EMPs. The mean percentage of piperacillin/tazobactam solution administered was significantly lower for the 75mg/mL EMP, with mean differences of -7.5% (95% CI [3.4, 11.6]; p<0.001) and -9.7% (95% CI [4.2, 15.2]; p=0.001) compared with the piperacillin tazobactam 56.25mg/mL (13.5g/240mL) and 37.5mg/mL (9g/240mL) EMPs respectively. Conclusion: The piperacillin/tazobactam 75mg/mL (18g/240mL) solution significantly slowed the rate of infusion from the EMP compared to the piperacillin/tazobactam 37.5mg/mL (9g/240mL) and piperacillin/tazobactam 56.25mg/mL (13.5g/240mL) solutions. The appropriateness of piperacillin/tazobactam 75mg/mL (18g/240mL) EMPs in the clinical HITH setting should be carefully considered.

  • Open Access

    A New Integrative Modeling Approach for Generating Counterfactual Projections of Colorectal Cancer Incidence Rates in the Absence of Organized Screening in Australia

    by Qingwei Luo, Jie-Bin Lew, Joachim Worthington, Clare Kahn, Han Ge, Emily He, Michael Caruana, Michael David, Dianne L O’COnnell, Karen Canfell, et al.

    Background: The Australian National Bowel Cancer Screening Program (NBCSP), which provides 2-yearly screening to people aged 50 to 74 y, had a phased rollout from 2006 and was fully implemented in 2020. To measure the effectiveness of the NBCSP accounting for age-specific trends, we aimed to develop a novel integrative method to project colorectal cancer (CRC) incidence rates from 2006 to 2045 in the absence of the NBCSP (referred to as “no-NBCSP projections”) while addressing the challenge of complex age-specific trends in CRC incidence. Methods: We constructed a new dataset by replacing the observed data for NBCSP-eligible individuals aged 50 to 74 y with intermediate projections based on pre-NBCSP data from 1982 to 2005. We compared the no-NBCSP CRC incidence projected using a standard age-period-cohort (APC) model, age-stratified APC models, and the integrative modeling approach. Results: The integrative modeling approach captured complex age-specific trends better than the standard and age-stratified APC models did. Without the NBCSP, the overall CRC incidence rates would be expected to decline from 2005 to 2025, followed by increases from 2026 to 2045. The incidence rates for those aged <50 y would be projected to continue increasing to 2045, and an increase in incidence rates for older age groups would be projected to occur from 2020 for ages 50 to 54 y, from 2030 for ages 65 to 74 y, and from 2035 for ages 75 y and older. Conclusions: These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia, and they have been used as new calibration targets for a simulation model of CRC and screening in Australia. The methods developed here could be used to generate comparators to assess the impact of other public health interventions. Highlights: We constructed counterfactual projections of colorectal cancer (CRC) incidence rates in the absence of the National Bowel Cancer Screening Program (no-NBCSP projections). To do this, we developed a new integrative modeling approach to capture complex age-specific colorectal cancer incidence trends. These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia. These projections stress the need for ongoing assessment of the starting age for the NBCSP, to tackle the increasing incidence for people younger than 50 y.


  • Open Access

    A population-representative serosurvey estimating vaccine-induced immunity against measles, rubella, hepatitis B and severe acute respiratory syndrome coronavirus 2 in Timor-Leste

    by Paul Arkell, Maria Y. Tanesi, Nelson Martins, Nelia Gomes, Tessa Oakley, Vanessa Solano, Michael David, Salvador Amaral, Sarah L. Sheridan, Teem-Wing Yip, et al.


  • Top Cited Papers

    The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis

    by Richa Shah, Nader Mounir Hanna, Ching Ee Loo, Michael David, Allini Mafra, Hanna Fink, Ethna McFerran, Montse Garcia, Robabeh Ghodssighassemabadi, Suryakanta Acharya, et al.

    The coronavirus disease 2019 pandemic substantially impacted the delivery of cancer services and programs. Here we reviewed and synthesized the global scale and impact of pandemic-related delays and disruptions on cancer services, including diagnosis, diagnostic procedures, screening, treatment and supportive and palliative care. Based on data from 245 articles in 46 countries, we observed declines in the number of cancer screening participation (39.0%), diagnoses (23.0%), diagnostic procedures (24.0%) and treatment (28.0%), ranging from a 15.0% decline for radiotherapy to a 35.0% decline for systemic treatment during the pandemic compared to during the prepandemic period. Medium-human development index (HDI) category countries experienced greater reductions than high- and very-high-HDI countries. Missing data from low-HDI countries emphasize the need for increased investments in cancer surveillance and research in these settings. PROSPERO registration: CRD42022301816


  • Open Access

    The association between vaping and subsequent initiation of cigarette smoking in young Australians from age 12 to 17 years: a retrospective cohort analysis using cross-sectional recall data from 5114 adolescents

    by Sam Egger, Michael David, Christina Watts, Anita Dessaix, Alecia Brooks, Emily Jenkinson, Paul Grogan, Marianne Weber, Qingwei Luo, Becky Freeman


  • Factors Influencing Time From Diagnosis to Treatment of Breast Cancer and the Impact of Longer Waiting Time on Survival in Kathmandu Valley, Nepal: A Population-Based Study

    by Ranjeeta Subedi, Nehmat Houssami, Carolyn Nickson, Meghnath Dhimal, Michael David, Xue Qin Yu

    PURPOSE: Longer time between breast cancer (BC) diagnosis and treatment initiation is associated with poorer survival, and this may be a factor behind disparities in global survival rates. We assessed time to BC treatment in the Kathmandu Valley, Nepal, including factors associated with longer waiting times and their impact on survival. METHODS: We conducted a retrospective population-based study of BC cases recorded in the Kathmandu Valley Population-Based Cancer Registry between 2018 and 2019. Fieldwork survey through telephone was undertaken to collect additional sociodemographic and clinical information. Logistic regression was performed to identify factors associated with longer time to treatment, and Kaplan-Meier and Cox proportional hazard regression was used to examine survival time and evaluate the association between longer time to treatment and survival. RESULTS: Among the 385 patients with BC, one third waited >4 weeks from diagnosis to initial treatment. Lower education was associated with longer time to treatment (adjusted odds ratio, 1.63 [95% CI, 1.03 to 2.60]). The overall 3-year survival rate was 88.6% and survival was not associated with time to treatment ( P = .50). However, advanced stage at diagnosis was associated with poorer survival (adjusted hazard ratio, 4.09 [95% CI, 1.27 to 13.23]). There was some indication that longer time to treatment was associated with poorer survival for advanced-stage patients, but data quality limited that analysis. CONCLUSION: In the Kathmandu Valley, Nepal, women with a lower education tend to wait longer from BC diagnosis to treatment. Patients with advanced-stage BC had poorer survival, and longer waiting time may be associated with poorer survival for women diagnosed with advanced-stage disease.


  • Open Access

    Estimates of the eligible population for Australia’s targeted National Lung Cancer Screening Program, 2025-2030

    by Stephen Wade, Preston Ngo, Yue He, Michael Caruana, Julia Steinberg, Qingwei Luo, Michael David, Annette McWilliams, Kwun M Fong, Karen Canfell, et al.

    Australia’s National Lung Cancer Screening Program will commence in July 2025, targeted at individuals aged 50-70 years with a 30 pack-year smoking history, who either currently smoke or have quit within the last 10 years. We forecasted the number of screening-eligible individuals over the first 5 years of the program using data from the 2019 National Drug Strategy Household Survey, and the 2022 Australian Bureau of Statistics population projections. Multiple imputation integrated with predictive modelling of future or unmeasured smoking characteristics was used to address missing data and simultaneously, to project individuals’ smoking histories to 2030. In 2025, 930,500 (95% prediction interval 852,200-1,019,000) individuals were estimated to be eligible, with the number meeting the criteria declining slightly over the years 2025-2030 in all Australian jurisdictions. Overall, 26-30% of those eligible will have quit smoking, and 70-74% will currently smoke. These estimates can be used in resource planning and as an indicative denominator to track participation rates for the program over time.


  • Open Access

    Cost-Effectiveness of an Intensive Upper Limb Rehabilitation Therapy for Children With Unilateral Cerebral Palsy: An Economic Evaluation of a Randomized Controlled Trial

    by Michael C. David, Hideki Higashi

    Background: Unilateral cerebral palsy is a major cause of childhood disability and a substantial economic burden. Intensive group-based therapy, consisting of hybrid constraint-induced movement and bimanual therapies, has been shown to be effective in improving specific quality-of-life domains in children with this disability. Our objective in this study was to assess if this intervention was cost-effective compared with standard care. Methods: An open-label, parallel, randomized controlled trial with an embedded economic evaluation of the intervention was conducted. A total of 47 children were randomized to either the intervention group (n = 27) or the standard care (n = 20) group. The effectiveness of the intervention was assessed using the Cerebral Palsy Quality of Life (Child) questionnaire across several domains. Nonparametric bootstrapping was used to quantify uncertainty intervals (UIs) for incremental cost-effectiveness ratios. Results: The incremental cost-effectiveness ratios for the intervention were $273 (95% UI: $107 to $945) for Pain and Impact of Disability, $1071 (95% UI: -$5718 to $4606) for Family Health and $1732 (95% UI: -$6448 to $8775) for Access to Services. For the 4 remaining domains, the intervention was dominated by standard care. At a willingness-to-pay threshold of $1000, only for the Pain and Impact of Disability domain was the intervention likely to have a probability of being cost-effective exceeding 0.75. Conclusions: Other than the Pain and Impact of Disability domain, there was insufficient evidence demonstrating the intervention to be cost-effective over a 13-week time horizon.


  • Open Access

    Cost-Effectiveness of an Intensive Upper Limb Rehabilitation Therapy for Children With Unilateral Cerebral Palsy: An Economic Evaluation of a Randomized Controlled Trial

    by Michael C. David, Hideki Higashi

    Background: Unilateral cerebral palsy is a major cause of childhood disability and a substantial economic burden. Intensive group-based therapy, consisting of hybrid constraint-induced movement and bimanual therapies, has been shown to be effective in improving specific quality-of-life domains in children with this disability. Our objective in this study was to assess if this intervention was cost-effective compared with standard care. Methods: An open-label, parallel, randomized controlled trial with an embedded economic evaluation of the intervention was conducted. A total of 47 children were randomized to either the intervention group (n = 27) or the standard care (n = 20) group. The effectiveness of the intervention was assessed using the Cerebral Palsy Quality of Life (Child) questionnaire across several domains. Nonparametric bootstrapping was used to quantify uncertainty intervals (UIs) for incremental cost-effectiveness ratios. Results: The incremental cost-effectiveness ratios for the intervention were $273 (95% UI: $107 to $945) for Pain and Impact of Disability, $1071 (95% UI: -$5718 to $4606) for Family Health and $1732 (95% UI: -$6448 to $8775) for Access to Services. For the 4 remaining domains, the intervention was dominated by standard care. At a willingness-to-pay threshold of $1000, only for the Pain and Impact of Disability domain was the intervention likely to have a probability of being cost-effective exceeding 0.75. Conclusions: Other than the Pain and Impact of Disability domain, there was insufficient evidence demonstrating the intervention to be cost-effective over a 13-week time horizon.